- **CPT Code Expansion**: 30 new conditions expand addressable market to 30M+ patients, effective 2027.
- **Revenue Growth**: Recurring revenue +3% YoY, gross billings per device $5,981 (+8.5% YoY).
- **Litigation Recovery**: $1M in regained revenue from 24 clinics, potential for 75-100+ additional recoveries.
- **Mexico Expansion**: TheraClearX first commercial placement, targeting 3,000+ dermatologists in Q4 2025.
- **Financial Resilience**: Gross margin stable at 60%, operating expenses down 21% YoY.

**【CEO Summary Section】**
- Expanded CPT codes for XTRAC excimer laser treatments to include 30 new conditions (e.g., vitiligo, atopic dermatitis), tripling the addressable patient population to over 30 million, effective January 1, 2027.
- 99 partner clinics in the Elevate 360 program achieved 7% YoY revenue growth, with average gross billings per device at $5,981 (8.5% YoY increase).
- Recovered $1M in recurring revenue from 24 clinics misled by competitor's false claims about PALLAS solid-state lasers.
- TheraClearX received regulatory approval in Mexico, with first commercial placement and plans for U.S.-style revenue-sharing agreements.

**【CFO Financial Commentary】**
- Q3 2025 total revenue: $6.9 million (-20% YoY), driven by international trade policy challenges.
- Recurring revenue: $5.5 million (+3% YoY); equipment revenue: $1.4 million (-60% YoY).
- Gross profit: $4.2 million (60% margin, flat YoY); operating expenses: $5.4 million (-21% YoY).
- Net loss: $1.6 million (-24% YoY); cash: $7.1 million.

**【Q&A Highlights】**
- DTC campaign efficiency: 8.5% increase in gross billings per device, with better cost per acquisition and show rates.
- Mexico strategy: TheraClearX registered with COFEPRIS, targeting 3,000+ dermatologists for placements in Q4 2025.
- Litigation: 2 dozen clinics returned to XTRAC, with potential for additional recoveries from 75-100 accounts misled by competitor.
- CPT code timeline: Expanded codes finalized for 2027, no temporary codes for 2026 to avoid market confusion.

STRATA Skin Sciences, Inc. (SSKN) Q3 2025 Earnings Call Transcript

- **Market Expansion**: CPT code expansion triples TAM to 30M patients, with potential 2026 G code acceleration.
- **Litigation Strength**: $10M+ damages claimed against LaserOptek for false advertising; new defendants added to ensure recovery.
- **Revenue Challenges**: Q2 2025 revenue down 9% YoY to $7.7M, driven by 15% international decline and U.S. device underutilization.
- **Legal Costs**: Q2 legal expenses: $340K; total lawsuit-related costs expected to exceed $1M in 2025.
- **Key Growth Driver**: 19 new U.S. placements in Q2 (highest in 6 quarters), signaling renewed partner confidence.

**【CEO Summary Section】**
- Expanded CPT codes for XTRAC 308-nm excimer laser now cover 30+ indications, including vitiligo, atopic dermatitis, and CTCL, tripling the total addressable market (TAM) to 30 million patients.
- Temporary G codes could accelerate revenue by 1 year, with potential reimbursement rate increases based on submitted economic data.
- Installed base optimization: Removed 21 underperforming devices, added 19 new placements (highest in 6 quarters), ending Q2 with 844 units in the U.S.
- DTC campaigns generated 1,100 appointments (61% show rate) and RDX system handled 5,100 patients, including 2,500 psoriasis and 1,000 acne cases.
- Litigation against LaserOptek for false advertising claims damages in the $10+ million range; new defendants added to ensure recovery.
- Q2 international revenue declined 15% YoY to $2.6M due to China trade disruptions, but strong underlying demand in Asia-Pacific markets.

**【CFO Financial Commentary】**
- Total Q2 2025 revenue: $7.7M (-9% YoY), with U.S. recurring billings at $4.7M (-2% YoY) and equipment revenue at $2.5M (-18% YoY).
- Gross profit: $4.3M (56% of revenue), down from $5.0M YoY due to lower sales and higher manufacturing costs.
- Operating expenses: $6.5M (+$1M YoY), driven by +16% selling/marketing and +$340K legal costs for the LaserOptek lawsuit.
- Adjusted EBITDA loss: $762K; cash balance: $6M.

**【Q&A Key Highlights】**
- **International Business Outlook**: Q2 2025 international revenue down 15% YoY; 2025H2 expected to mirror 2024H2 trends, but tariffs remain a risk.
- **Lawsuit Costs**: Q2 legal expenses: $340K; total expected damages: $8-10M; discovery phase nearing completion.
- **Temporary G Codes Timeline**: CMS 2026 final rule expected in November 2025; potential 2026 implementation with higher reimbursement rates.
- **Elevate 360 Impact**: 100+ clinics optimized; one Florida clinic increased patient utilization from 6% to 25% after program implementation.
- **TheraClearX Growth**: Installed base: 161 units (vs. 117 in Q2 2024); focus on XTRAC as primary growth driver.

STRATA Skin Sciences, Inc. (SSKN) Q2 2025 Earnings Call Transcript

- **Revenue Resilience**: Q1 2025 recurring revenue growth streak continues at 4 quarters YoY, with XTRAC utilization gains.
- **Strategic Breakthrough**: Elevate 360 program expanded to 100 accounts, driving $15M+ incremental revenue potential.
- **TheraClearX Surge**: 160 devices deployed, 1,000 patients processed Q1, 138% YoY growth in reimbursement volume.
- **Profitability Boost**: Gross margin 53.5%, best Q1 EBITDA since 2022, with operating expenses down 5% YoY.
- **Tariff Risk**: 145% tariffs threaten 50%+ international revenue decline if unresolved, impacting warranty parts supply chains.
- **Cash Position**: $7.8M cash (including $1.3M restricted), improving cash burn to $749K Q1 (vs. $1.55M prior year).


**【Management Opening Remarks】**
- STRATA Skin Sciences released Q1 2025 financial results, highlighting execution of its turnaround strategy.
- CEO Dolev Rafaeli emphasized focus on optimizing device utilization, Direct-to-Consumer (DTC) marketing, and international expansion despite tariff risks.

**【CEO Commentary】**
- **Revenue Growth**: Q1 2025 marks the fourth consecutive quarter of year-over-year growth in average net recurring revenue per XTRAC device in the US.
- **Strategy Execution**: Elevate 360 consulting program expanded to 100 accounts, driving device utilization and revenue. For example, one partner clinic increased revenue from $13,000 to $28,000 QoQ through program implementation.
- **TheraClearX Momentum**: Installed base grew to 160 devices (vs. 104 in Q1 2024), with 1,000 patients processed through reimbursement support (up 138% YoY).
- **Tariff Risk**: Warning that unresolved tariffs could reduce international revenue by 50%+ in future quarters.

**【CFO Financial Commentary】**
- **Revenue**: Total Q1 2025 revenue $6.8M (flat YoY), with recurring revenue $4.7M (up 1% YoY).
- **Profitability**: Gross margin improved to 53.5% (vs. 45.6% Q1 2024), driven by recurring revenue efficiency. Non-GAAP EBITDA $732K (best since Q1 2022).
- **Cost Control**: Operating expenses down 5% YoY to $5.7M, with engineering costs reduced 60%.
- **Cash Flow**: Cash burn $749K (vs. $1.55M Q1 2024), ending with $7.8M cash (including $1.3M restricted for tax audit).

**【Q&A Highlights】**
- **TheraClearX Pipeline**: Full deployment of 250 owned devices expected by Q1 2026. Each patient generates $300+ in revenue, with 1,000 Q1 patients translating to $1.8M annualized revenue.
- **Utilization Trends**: XTRAC breakeven at $18K/device/year, TheraClearX at $9K/device/year. Q1 2025 saw 6,000 TheraClearX procedures (24,000 annualized).
- **Tariff Impact**: 145% tariffs on Asian imports could disrupt warranty parts supply chains, potentially halting international sales growth.
- **Installed Base Strategy**: Focus on redeploying 100+ idle devices into high-potential clinics via Elevate 360, with 7 new deployments in Q1 2025.


STRATA Skin Sciences, Inc. (SSKN) Q1 2025 Earnings Call Transcript

- **Revenue Growth**: Q4 2024 total revenue up 10% YoY to $9.6M, driven by international sales ($4.1M, +41% YoY) and improved U.S. device utilization.
- **Profitability Boost**: Gross margin expands to 60.1% (vs. 55.3% YoY), operating loss down 68% YoY.
- **TheraClearX Momentum**: 144 devices installed, 108 now billing insurance, with >3,700 patient preauthorizations.
- **Strategic Focus**: Removing underperforming accounts (10% annual churn), prioritizing high-volume clinics with >1,000 relevant patients.

**【CEO Opening Remarks】**
- **Revenue Performance**: Q4 2024 total revenue $9.6M, up 10% YoY. U.S. XTRAC installed base declined to 864 units but average gross billing per device rose 5% YoY to $5,637, driven by strategic focus on high-performing clinics.
- **Gross Margin Improvement**: Q4 gross margin 60.1%, up 480bps YoY, nearing 2019-2021 peak levels of ~70%.
- **International Growth**: International sales $4.1M (27% QoQ, 41% YoY), led by Japan with ~100 XTRAC devices sold since 2019.
- **TheraClearX Expansion**: 144 devices installed (up from 92 in 2023), with 108 now billing insurance and >3,700 patient preauthorizations secured.

**【CFO Financial Details】**
- **Revenue Breakdown**: Q4 2024 total revenue $9.6M (10% YoY growth). Equipment revenue $3.8M (29% YoY), driven by international sales. Recurring billings $4.87M (down 1.5% YoY).
- **Profitability**: Gross profit $5.8M (12% YoY), operating loss improved 68% YoY (adjusted for non-cash charges). Cash balance $8.6M, supporting 2025 growth initiatives.
- **Cost Management**: Normalized operating expenses $6.1M (flat YoY), reflecting disciplined expense control.

**【Q&A Highlights】**
- **TheraClearX Adoption**: Northeast clinics leading with 1-2 device pilots, achieving 86% patient preauthorization rates. Expanding to private equity-backed groups with >15 devices.
- **International Drivers**: Japan's high patient volume (devices used 20-50x more frequently than U.S.), China's public-private hospital adoption, and Middle East's shift from public tenders to private clinics.
- **Account Management Strategy**: Removing ~10% underperforming accounts annually, replacing with high-potential clinics (e.g., 1,000+ relevant patients per office).

Actual							-0.1733	-0.5	-0.4	-0.1	-0.7	0.3	-0.2	-0.1635	-0.6694	-0.4683	-0.3	0.4495	-0.2045	-0.0248	0.3972	-0.4162	-0.4316	0.5333	-0.192	-0.8646	-0.2281	-0.186	0.0042
Forecast							-0.5333	-0.3333	-0.3667	-0.2667	-0.3667	-0.5333	-0.5	-0.25	-0.6	-0.5	-0.6	-0.5	-0.7	-0.55	-0.4	-0.2	-0.65	-0.7	-0.4448	-0.3	-0.515	-0.2877	-0.53
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+67.50%	-50.02%	-9.08%	+62.50%	-90.89%	+156.25%	+60.00%	+34.60%	-11.57%	+6.34%	+50.00%	+189.90%	+70.79%	+95.49%	+199.30%	-108.10%	+33.60%	+176.19%	+56.83%	-188.20%	+55.71%	+35.35%	+100.79%

SSKN(Delisted)

SSKN fundamentals

SSKN Q3 2025 Earnings

Earnings Call

You can ask Aime